After 1 stimulation, Her2-bridging CAR-CD19 T cells were able to kill 100% of target tumor cells, whether JeKo-1 B cells or SKOV3 ovarian carcinoma cells (Fig 4B). This evidence concerns the gene ERBB2 and ovarian carcinoma.